![merckincweb2](https://pharmafile.com/wp-content/uploads/2019/06/merckincweb2_6-1024x719.jpg)
FDA approves new indication for MSD’s Zerbaxa
pharmafile | June 5, 2019 | News story | Research and Development | Merck, Zerbaxa, bacterial infection, pharma
The FDA has approved US firm Merck’s Zerbaxa (ceftolozane and tazobactam) for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
The new indication comes after MSD’s drug was first approved for treating complicated intra-abdominal infections and urinary tract infections by the FDA in 2014.
The drug showed similar efficacy to another antibacterial drug in a clinical trial of 726 patients who had been hospitalised with HABP/VABP.
Elevated liver enzyme levels, renal impairment or failure, and diarrhea were amongst the most commonly reported adverse reactions.
Louis Goss
Related Content
![](https://pharmafile.com/wp-content/uploads/2023/08/nappy-5RDjrd5GXuM-unsplash-300x200.jpg)
FDA approves Merck’s Capvaxive for prevention of pneumococcal disease
Merck, known as MSD outside of the US and Canada, has announced that the US …
![](https://pharmafile.com/wp-content/uploads/2023/05/amanda-dalbjorn-UbJMy92p8wk-unsplash-300x200.jpg)
Merck to acquire EyeBio for an upfront $1.3bn
Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced …
![](https://pharmafile.com/wp-content/uploads/2023/05/national-cancer-institute-pX_cWEBhzZQ-unsplash-295x300.jpg)
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
Merck, known as MSD outside of the US and Canada, has announced results from the …